Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity
General and abdominal obesity are the major subtypes of obesity. Compared with general obesity, abdominal obesity was considered to be more closely associated with chronic diabetes complications, such as cardiovascular diseases and diabetic retinopathy (1,2). Although the association between abdominal obesity and urinary albumin was reported in previous studies (3–5), whether abdominal obesity is more closely associated with diabetic kidney disease (DKD) than general obesity has not been reported yet.
Two studies were carried out to investigate the association of general and abdominal obesity with DKD. Study A was a cross-sectional study. Body composition was assessed using DXA among 1,016 patients with type 2 diabetes (T2D). General obesity parameters, including BMI, total body fat percentage (TBF), and fat mass index (FMI), and abdominal obesity parameters, including waist circumference (WC), waist-to-height ratio (WHtR), and visceral adipose tissue (VAT), were measured. DKD is defined as chronic kidney disease (CKD) stage 3–5 (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2). Study B was a 5-year prospective study in which 279 T2D patients without DKD at baseline were followed up. BMI, WC, and WHtR were used as indicators of obesity in study B. Obesity-related parameters were split into tertiles, and subjects were stratified into those with low, median, and high values accordingly.
In study A, there were 470, 374, and 172 patients in CKD stage 1, stage 2, and stage 3–5, respectively. Participants with higher values of BMI, TBF, FMI, WC, WHtR, and VAT were more likely to have a lower eGFR, as compared with those with lower values. Logistic regression analyses showed that parameters of general obesity (BMI, TBF, or FMI) were associated with risk of DKD; however, the correlation disappeared when VAT was adjusted. Compared with subjects with low values of WC, WHtR, or VAT, those with median and high values had increased risk of DKD after adjusting BMI (low values were the references, odds ratio [OR] 0.92 [95% CI 0.57, 1.48] for median values, 1.56 [1.11, 2.77] for high values, P for trend = 0.044 for WC; 1.40 [0.86, 2.27], 2.61 [1.47, 4.63], P for trend = 0.003 for WHtR; 1.53 [0.95, 2.46], 2.84 [1.66, 4.84], P for trend <0.001 for VAT). The associations between the risk of DKD and WC, WHtR, or VAT remained the same after multivariate adjustment (Fig. 1). In study B, 41 subjects had eGFR ≤60 mL/min/1.73 m2 after 6 years of follow-up. No relationship of BMI and risk of DKD was found in crude, WHtR-adjusted, or multivariate-adjusted models. Abdominal obesity parameters were significantly associated with risk of DKD after adjustment for BMI (low values were the references, OR 1.91 [95% CI 0.73, 5.03] for median values, 3.26 [1.16, 9.12] for high values, P for trend = 0.025 for WC; 1.72 [0.66, 4.45], 2.85 [1.14, 7.10], P for trend = 0.025 for WHR; 3.11 [1.08, 8.98], 5.85 [1.89, 12.17], P for trend = 0.009 for WHtR). The associations between the risk of DKD and WC, WHR, or WHtR remained the same when other confounders were adjusted.
Our studies indicate that abdominal obesity is more closely associated with DKD than general obesity. Of note, the relationships between abdominal obesity and DKD were independent of BMI and other known risk factors such as age, duration of diabetes, blood pressure, blood glucose, and medication use. BMI, a widely used parameter of general obesity, was not significantly associated with the risk of DKD after adjusting for abdominal obesity parameters such as VAT or WHtR. The current study expands the current body of knowledge on the association of obesity with DKD and highlights abdominal obesity as a more important risk factor for DKD in T2D patients than general obesity.
Acknowledgments. The authors thank Laboratory of Endocrine and the Laboratory of Lipid & Glucose Metabolism, the First Affiliated Hospital of Chongqing Medical University.
Funding. This research was supported by the National Key Clinical Specialties Construction Program of China, the National Natural Science Foundation of China (81370954), and The Fundamental Science & Advanced Technology Research of Chongqing (Major Project, cstc2015jcyjBX0096).
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. J.H. and S.Y designed the study, oversaw the data collection, and wrote the manuscript. A.Z. and P.Y. conducted the data analysis and contributed to the writing of the manuscript. X.C. and X.L. contributed to the study design, provided statistical expertise, and contributed to the writing of the manuscript. R.G. and Y.W. assisted with the data collection and contributed to the writing and editing of the manuscript. T.L. contributed to the writing of the manuscript. K.L. assisted with the data collection. Q.C. and X.X. designed the study and edited the manuscript. Q.L. oversaw the study and revised the manuscript. Q.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
- Received May 11, 2016.
- Accepted July 27, 2016.
- © 2016 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.